The foundations of immune checkpoint blockade and the ipilimumab approval decennial
AJ Korman, SC Garrett-Thomson…�- Nature Reviews Drug�…, 2022 - nature.com
Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer�…
discussion and experimentation for over a hundred years. Several successful cancer�…
Fundamental mechanisms of immune checkpoint blockade therapy
SC Wei, CR Duffy, JP Allison�- Cancer discovery, 2018 - AACR
Immune checkpoint blockade is able to induce durable responses across multiple types of
cancer, which has enabled the oncology community to begin to envision potentially curative�…
cancer, which has enabled the oncology community to begin to envision potentially curative�…
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the�…
A Marabelle, M Fakih, J Lopez, M Shah…�- The Lancet�…, 2020 - thelancet.com
Background Tumour mutational burden (TMB) has been retrospectively correlated with
response to immune checkpoint blockade. We prospectively explored the association of�…
response to immune checkpoint blockade. We prospectively explored the association of�…
[HTML][HTML] High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
Background High tumor mutation burden (TMB-H) has been proposed as a predictive
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for�…
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for�…
[HTML][HTML] The challenges of tumor mutational burden as an immunotherapy biomarker
DL Jardim, A Goodman, D de Melo Gagliato…�- Cancer cell, 2021 - cell.com
Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T�…
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T�…
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Checkpoint inhibitor-based immunotherapies that target cytotoxic T lymphocyte antigen 4
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success�…
(CTLA4) or the programmed cell death 1 (PD1) pathway have achieved impressive success�…
Nivolumab plus ipilimumab in lung cancer with a high tumor mutational burden
MD Hellmann, TE Ciuleanu, A Pluzanski…�- …�England Journal of�…, 2018 - Mass Medical Soc
Background Nivolumab plus ipilimumab showed promising efficacy for the treatment of non–
small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has�…
small-cell lung cancer (NSCLC) in a phase 1 trial, and tumor mutational burden has�…
[HTML][HTML] Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
Background Treatment with immune checkpoint blockade (ICB) with agents such as anti-
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or�…
programmed cell death protein 1 (PD-1), anti-programmed death-ligand 1 (PD-L1), and/or�…
[HTML][HTML] First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
L Horn, AS Mansfield, A Szczęsna…�- …�England Journal of�…, 2018 - Mass Medical Soc
Background Enhancing tumor-specific T-cell immunity by inhibiting programmed death
ligand 1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment�…
ligand 1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment�…
Intratumoral heterogeneity in cancer progression and response to immunotherapy
Most (if not all) tumors emerge and progress under a strong evolutionary pressure imposed
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these�…
by trophic, metabolic, immunological, and therapeutic factors. The relative impact of these�…